New treatment slows progression of rare blood cancer by 74%

By Agence France-Presse

Jun 07, 2023 12:32 am

A TREATMENT that involves genetically modifying the body's immune cells has been found to cut the risk of disease progression by 74 percent in people with a rare type of blood cancer, results showed Monday (Tuesday in Manila).

Ciltacabtagene autoleucel — also known by its trade name Carvykti — was tested in a clinical trial involving 419 patients with multiple myeloma, whose disease was not responsive to the current frontline drug lenalidomide, a chemotherapy medicine.

Already have an active account? Log in here to continue reading.
Or
Subscribe to the Premium Subscription plan to access this subscriber-exclusive article.

Related Articles

PhilHealth budget hiked to P284B despite subsidy cut

How to beat the holiday blues

Major quake crushes buildings in Vanuatu capital, bodies seen

Tulfo solidifies lead in survey

3 PH natural wonders among 5 Asean Heritage Parks

Candidates warned not to politicize govt aid

PNP to public: Avoid prohibited firecrackers